Key Facts
- CAS
- 83150-76-9
- Molecular Weight (MW)
- 1019.3 g/mol
- Half-life
- ~1.7 hours (sc); depot has prolonged release
- Unit
- mcg
- Administration Route
- Subcutaneous / Intramuscular (LAR)
- Frequency
- Three times daily (immediate-release) or monthly (LAR)
- Last updated
- 12/14/2025
Overview
—
Protocol
- Dosage Range
- 50-200 mcg three times daily (immediate-release) or 10-30 mg monthly (LAR depot)
- Frequency
- Three times daily (immediate-release) or monthly (LAR)
- Cycle
- Long-term use as prescribed
- Administration Route
- Subcutaneous / Intramuscular (LAR)
- Reconstitution Guide
- LAR formulation requires reconstitution per package insert
Science
Mechanism of Action
Mechanism of action not fully established in publicly available sources.
Studies are being curated for this entry.
Suggest a studyBenefits
Therapeutic benefits not fully established.
Potential Side Effects
- Side effects not fully established.
References
- FDA Label - SandostatinExternal link · Year —